Janux Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Janux Therapeutics, Inc. (JANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.02 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 309.60K shares, a 1.90% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.72M shares, a 29.03% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 40.13K shares, a 19.69% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 60.88K shares, a 59.11% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.73M shares, a 26.49% decline from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.36M shares, a 16.83% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.02M shares, a 10.36% decline from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.25M shares, a 56.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 309.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.02M shares 10-Q · filed 2026-08-06 | 2.07M shares derived: sum of 3 quarters · filed 2026-08-06 | 2.13M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.72M shares 10-Q · filed 2026-05-07 | 1.76M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.82M shares derived: sum of 3 quarters · filed 2026-05-07 | 2.12M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 40.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 101.00K shares derived: sum of 2 quarters · filed 2026-02-26 | 404.84K shares derived: sum of 3 quarters · filed 2026-02-26 | 1.73M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 60.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 364.71K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.69M shares 10-Q · filed 2025-11-06 | 1.73M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 303.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.63M shares 10-Q · filed 2025-08-07 | 1.67M shares derived: sum of 3 quarters · filed 2026-02-26 | 1.82M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 1.33M shares 10-Q · filed 2025-05-08 | 1.36M shares derived: sum of 2 quarters · filed 2026-02-26 | 1.51M shares derived: sum of 3 quarters · filed 2026-02-26 | 1.60M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 33.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 182.40K shares derived: sum of 2 quarters · filed 2026-02-26 | 268.20K shares derived: sum of 3 quarters · filed 2026-02-26 | 2.36M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 148.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 234.67K shares derived: sum of 2 quarters · filed 2024-11-06 | 2.33M shares 10-Q · filed 2024-11-06 | 2.36M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 85.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 2.18M shares 10-Q · filed 2024-08-07 | 2.21M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.22M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 2.09M shares 10-Q · filed 2024-05-08 | 2.13M shares derived: sum of 2 quarters · filed 2025-02-27 | 2.14M shares derived: sum of 3 quarters · filed 2025-02-27 | 2.38M shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 34.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 45.20K shares derived: sum of 2 quarters · filed 2025-02-27 | 289.45K shares derived: sum of 3 quarters · filed 2025-02-27 | 2.02M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 10.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 254.65K shares derived: sum of 2 quarters · filed 2023-11-07 | 1.98M shares 10-Q · filed 2023-11-07 | 2.12M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 244.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.97M shares 10-Q · filed 2023-08-08 | 2.11M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.19M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.73M shares 10-Q · filed 2023-05-09 | 1.87M shares derived: sum of 2 quarters · filed 2023-05-09 | 1.94M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.37M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 137.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | 213.63K shares derived: sum of 2 quarters · filed 2023-03-10 | 641.38K shares derived: sum of 3 quarters · filed 2023-03-10 | 2.25M shares 10-K · filed 2023-03-10 |
| 2022-09-30 | 76.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 504.38K shares derived: sum of 2 quarters · filed 2022-11-10 | 2.12M shares 10-Q · filed 2022-11-10 | 2.22M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 427.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 2.04M shares 10-Q · filed 2022-08-09 | 2.15M shares derived: sum of 3 quarters · filed 2022-08-09 | 2.56M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 1.61M shares 10-Q · filed 2022-05-10 | 1.72M shares derived: sum of 2 quarters · filed 2022-05-10 | 2.13M shares derived: sum of 3 quarters · filed 2022-05-10 | |
| 2021-12-31 | 107.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 518.11K shares derived: sum of 2 quarters · filed 2022-03-18 | 5.23M shares 10-K · filed 2022-03-18 | |
| 2021-09-30 | 410.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 5.12M shares 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | 4.71M shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |